Dianthus Therapeutics, Inc. (DNTH) AI Stock Analysis

Headquartered in New York, New York, Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company advancing complement therapeutics tailored for patients with severe autoimmune and inflammatory conditions. Its lead candidate is DNTH103, a monoclonal antibody currently in Phase 2 clinical trials. DNTH103 is being evaluated for efficacy in disorders including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Founded in 2019, the company focuses on leveraging complement biology to develop targeted treatments addressing unmet medical needs. Dianthus Therapeutics employs 92 people and utilizes New York City scientific and clinical resources to advance its pipeline.

Dianthus Therapeutics generated revenue of $2.0M in FY2025, representing a decline of 67.3% following $6.2M in FY2024 and $2.8M in FY2023. Across the four-year period from FY2021 to FY2025, revenue grew at an 8.4% compound annual growth rate. Operating margin was -8739.3% in FY2025, while net income was -$162.3M and diluted EPS was -$4.10, driven by $145.6M in research and development expenses. Over the trailing twelve months through June 30, 2026, revenue totaled $1.9M with an operating margin of -8079.1% and EPS of -$4.24, while quarterly revenue grew 294.3% year-over-year in the latest quarter.

As of June 30, 2026, Dianthus Therapeutics held $886.8M in cash and short-term investments against total debt of $1.3M, leaving net cash of $885.5M. Total assets were $1.21B and shareholders' equity was $1.17B, with a current ratio of 26.10 and a debt-to-equity ratio of 0.00. For FY2025, operating cash flow stood at -$129.1M and free cash flow was -$129.3M. Cash use included $213,000 in capital expenditures and proceeds from share issuance of $317,000.

With a market capitalization of $4.03B and an enterprise value of $4.34B, Dianthus Therapeutics trades at a price-to-book ratio of 4.5x. For context, the median of its US-listed Healthcare peers trades at a price-to-sales ratio of 4.1x and a forward P/E of 17.3x. Over the past year, the stock gained 100.2%, outperforming the 16.8% return for the S&P 500 (SPY). Over a five-year period, the stock fell 33.1%, trailing the 83.0% gain of the benchmark index.

Wall Street analysts hold 16 Strong Buy ratings and 1 Buy rating, with no Hold or Sell recommendations. The mean price target is $140.80, which is 95.3% above the October 16, 2026 closing price of $72.09. For the current fiscal year ending December 31, 2026, consensus estimates project EPS of -$3.81 and revenue of $1.9M. For the following fiscal year, 11 analysts project EPS of -$4.61 and revenue of $1.8M. The company beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of Dianthus Therapeutics, Inc. (DNTH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DNTH income statement, DNTH balance sheet, DNTH key metrics, DNTH analyst forecast, DNTH chart. See the DNTH stock overview for the latest quote and news.